Kura Oncology, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Troy Wilson
- Full Time Employees
- 260
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4930 Directors Place San Diego CA United States of America 92121
- IPO Date
- Sep 16, 2015
- CIK
- 0001422143
- Website
- kuraoncology.com
- Similar Companies
- Business
- Kura Oncology, Inc. (KURA) develops precision medicines targeting cancer signaling pathways for blood cancers and solid tumors. The company focuses on small molecule drug candidates, including its lead menin inhibitor ziftomenib for NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (AML) in monotherapy and combinations with therapies such as venetoclax/azacitidine, cytarabine/daunorubicin (7+3), gilteritinib, FLAG-IDA, and low-dose cytarabine (LDAC); next-generation farnesyl transferase inhibitor (FTI) darlifarnib (KO-2806) in monotherapy and combinations with cabozantinib or adagrasib for KRAS G12C-mutant non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC); tipifarnib, an oral FTI, in combination with alpelisib for head and neck squamous cell carcinoma (HNSCC) with HRAS mutations; and a next-generation menin inhibitor in research. Kura Oncology, founded in 2014, maintains headquarters in San Diego, California, with additional operations in Boston, Massachusetts, and conducts global clinical trials targeting genetically defined patient populations in oncology. In November 2024, the company enters a global strategic collaboration with Kyowa Kirin Co., Ltd. to co-develop and commercialize ziftomenib for AML and other hematologic malignancies, featuring a $330 million upfront payment, up to $1.161 billion in milestones including $420 million near-term, 50/50 U.S. profit-sharing, tiered double-digit royalties, and Kyowa Kirin's opt-in for solid tumors like gastrointestinal stromal tumors (GIST); Kura advances ziftomenib combinations to registration-enabling trials such as KOMET-017 for frontline AML in the second half of 2025, initiates Phase 1 KOMET-015 with imatinib for advanced GIST, and plans data presentations on FTIs at the European Society for Medical Oncology Congress in October 2025.
Company News
Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
Kura Oncology to Participate in Three Investor Conferences in September
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects
Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?
Kura Oncology (KURA) CEO Purchases Shares Amid Positive KOMZIFTI Launch Metrics
Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?
Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect?
Assenagon Asset Management S.A. Trims Holdings in Kura Oncology, Inc. $KURA
Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript
Kura Oncology Q2 Earnings Call Highlights
Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates
Kura Oncology Reports Second Quarter 2026 Financial Results
Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)